CD274 and neoplasm: Abundant evidence indicates that cancer immunotherapy response is associated with certain genetic or genomic features, such as PD-L1 expression [8], DNA mismatch repair deficiency [9], tumor mutation burden (TMB) [10], and tumor aneuploidy [11].